Drug class: GLP-1 RA Mechanism of Action Liraglutide is a human GLP-1 analogue that activates GLP-1 receptors, enhancing glucose-dependent insulin secretion, suppressing glucagon secretion, slowing gastric emptying, and reducing appetite. This results in improved glycemic control (1). Approved Indications Type 2 diabetes mellitus (1) Cardiovascular risk reduction (1) Dosage and Administration Initial: 0.6 mg SC once daily for 1 week. Increase to 1.2 mg once daily, up to 1.8 m